BRD4-TARGETED THERAPY ABBV-744 CLINICAL DATA NO FURTHER A MYSTERY

In Segment A, contributors will get diverse doses and schedules of oral ABBV-744 tablet to recognize Protected dosing regimen. Supplemental members might be enrolled with the identified monotherapy dosign routine. In Segment B, members will acquire oral ruxolitinib and ABBV-744 might be presented as "include-on" therapy. In Phase C, individuals wil